Harpoon Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>HT</div>
HARP -- USA Stock  

USD 15.75  1.38  8.06%

Whilst many millenniums are getting more into healthcare space, it makes sense to recap Harpoon Therapeutics against current trends within the economy. As expected, Harpoon Therapeutics is starting to reaffirm its true potential as insiders are becoming more and more confident in the future outlook. The returns on investing in Harpoon Therapeutics and the market returns of the last few months appear highly unrelated. The symptom of healthy basic indicators of the firm suggests a short-term price swing for insiders of Harpoon. The next fiscal quarter end is expected on the 30th of September 2020. The stock is currently experiences an active upward rally.
Published over a month ago
View all stories for Harpoon Therapeutics | View All Stories
Is Harpoon Therapeutics (NASDAQ:HARP) about to rebound?
Harpoon Therapeutics's average rating is Strong Buy from 8 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Harpoon Therapeutics market sentiment investors' perception of the future value of Harpoon. Let us look at a few aspects of Harpoon technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Harpoon Therapeutics. In general, we focus on analyzing Harpoon Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Harpoon Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Harpoon Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Harpoon Therapeutics, we also check how macroeconomic factors affect Harpoon Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Harpoon Stands against Peers?

Analyzing Harpoon Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Harpoon Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Harpoon Therapeutics Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Harpoon Therapeutics, but it might be worth checking our own buy vs. sell analysis

A Deeper look at Harpoon

This firm has a beta of -0.0163. Let's try to break down what Harpoon's beta means in this case. The returns on MARKET and Harpoon Therapeutics are completely uncorrelated. The beta indicator helps investors understand whether Harpoon Therapeutics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Harpoon deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The big decline in price over the last few months for Harpoon Therapeuticsmay raise some interest from insiders. The stock closed today at a share price of 12.19 on 7,801,586 in trading volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in July. However, diversifying your holdings with Harpoon Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 5.96. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Harpoon Therapeutics partners.

Our take on today Harpoon Therapeutics roll up

Potential upside is down to 9.03. It may hint at a possible volatility decline. Harpoon Therapeutics exhibits very low volatility with skewness of 0.77 and kurtosis of 3.41. However, we advise investors to further study Harpoon Therapeutics technical indicators to make sure all market info is available and is reliable.

Our Takeaway on Harpoon Therapeutics Investment

Although some other entities in the biotechnology industry are either recovering or due for a correction, Harpoon Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. To summarize, as of the 23rd of August 2020, our research shows that Harpoon Therapeutics is a rather somewhat reliable investment opportunity with a very low probability of bankruptcy in the next two years. From a slightly different view, the entity currently appears to be undervalued. Our primary 30 days buy-hold-sell advice on the firm is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Harpoon Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com